Yarrow Bioscience, Inc. (YARW) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US92941V4077
Yarrow Bioscience, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 570,000.00 USD |
| Operating income | -29.75 m USD |
| EBIT | -26.48 m USD |
| Net income | -26.48 m USD |
| Diluted EPS – continuing operations | -0.62 USD |
Full history since 2014, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Yarrow Bioscience, Inc.
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
More stocks
- Inversiones Doalca SOCIMI SA (YDOA.MC)
- Shandong Longertek Technology Co Ltd (300594.SZ)
- SHOULDER INNOVATIONS, INC. (SI)
- Kao Hsiung Chang Iron & Steel Corp (2008.TW)
- InflaRx N.V. (IFRX)
- Hwacom Systems (6163.TWO)
- ThredUp Inc. (TDUP)
- NEXTEEL Co., Ltd. (092790.KS)
- SB FINANCIAL GROUP, INC. (SBFG)
- Sovereign Metals Ltd (SVM.AX)
- Trio Tech Intl Grp Co Ltd (6862.TW)
- Astra Graphia Tbk (ASGR.JK)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.